Literature DB >> 19377078

Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study.

François Girodon1, Gilles Bonicelli, Céline Schaeffer, Morgane Mounier, Serge Carillo, Ingrid Lafon, Paule Marie Carli, Inès Janoray, Emmanuelle Ferrant, Marc Maynadié.   

Abstract

To observe the effect of the new World Health Organization (WHO) criteria on the incidence of myeloproliferative neoplasms, we performed a retrospective study of a population-based registry in the Côte d'Or area, France, from 1980 to 2007. A total of 524 myeloproliferative neoplasms were registered for the 1980-2007 period, including 135 polycythemia vera, 308 essential thrombocythemia and 81 idiopathic myelofibroses. No change in the incidence of either polycythemia vera or idiopathic myelofibrosis was observed for the 2005-2007 period, compared to 1980-2004. On the contrary, a pronounced increase in the incidence of essential thrombocythemia was noted after 2005, mainly due to the use of JAK2 mutation screening and a lower threshold of platelet count. Our study confirms the relevance of the new WHO diagnostic criteria in allowing earlier diagnosis of essential thrombocythemia.

Entities:  

Mesh:

Year:  2009        PMID: 19377078      PMCID: PMC2688580          DOI: 10.3324/haematol.2008.004234

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  24 in total

1.  High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel.

Authors:  Y Chaiter; B Brenner; E Aghai; I Tatarsky
Journal:  Leuk Lymphoma       Date:  1992-06

2.  Incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the Côte d'Or area, France, during 1980-99.

Authors:  F Girodon; V Jooste; M Maynadie; B Favre; C Schaeffer; P Carli
Journal:  J Intern Med       Date:  2005-07       Impact factor: 8.989

3.  Diagnosis and classification of the polycythemias.

Authors:  N I Berlin
Journal:  Semin Hematol       Date:  1975-10       Impact factor: 3.851

4.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors:  Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

5.  Myeloproliferative disorders in Sweden: Incidence trends and multiple tumors.

Authors:  Kari Hemminki; Hui Zhang; Jan Sundquist; Justo Lorenzo Bermejo
Journal:  Leuk Res       Date:  2008-05-27       Impact factor: 3.156

6.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

7.  High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

Authors:  Jean-Jacques Kiladjian; Bruno Cassinat; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Marie-Laurence Menot; Gerald Massonnet; Jean-Luc Dutel; Kamel Ghomari; Philippe Rousselot; Marie-Jose Grange; Yasmina Chait; William Vainchenker; Nathalie Parquet; Lina Abdelkader-Aljassem; Jean-François Bernard; Jean-Didier Rain; Sylvie Chevret; Christine Chomienne; Pierre Fenaux
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

8.  Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.

Authors:  M K Jensen; P de Nully Brown; O J Nielsen; H C Hasselbalch
Journal:  Eur J Haematol       Date:  2000-08       Impact factor: 2.997

Review 9.  Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.

Authors:  Peter Johansson
Journal:  Semin Thromb Hemost       Date:  2006-04       Impact factor: 4.180

10.  Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989.

Authors:  B J Anía; V J Suman; J L Sobell; M B Codd; M N Silverstein; L J Melton
Journal:  Am J Hematol       Date:  1994-10       Impact factor: 10.047

View more
  7 in total

1.  Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).

Authors:  Marc Maynadié; François Girodon; Ines Manivet-Janoray; Morgane Mounier; Francine Mugneret; François Bailly; Bernardine Favre; Denis Caillot; Tony Petrella; Michel Flesch; Paule-Marie Carli
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 2.  Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.

Authors:  Ros Wade; Micah Rose; Aileen Rae Neilson; Lisa Stirk; Rocio Rodriguez-Lopez; David Bowen; Dawn Craig; Nerys Woolacott
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

3.  Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain.

Authors:  Gemma Osca-Gelis; Montserrat Puig-Vives; Marc Saez; David Gallardo; Natalia Lloveras; Rafael Marcos-Gragera
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

4.  Recent advances in bone marrow biopsy pathology.

Authors:  Jon van der Walt
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

5.  Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries.

Authors:  Marta Solans; Arantza Sanvisens; Alberto Ameijide; Susana Merino; Dolores Rojas; Araceli Alemán; Emilia Banqueri; Matilde Chico; Ana Isabel Marcos; Visitación de Castro; Leire Gil; Arantza López de Munain; Montse Puigdemont; Maria-José Sánchez; Josefina Perucha; Patricia Ruiz-Armengol; Mª Dolores Chirlaque; Marcela Guevara; Marià Carulla; Rafael Marcos-Gragera
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

6.  Philadelphia-negative chronic myeloproliferative neoplasms.

Authors:  Rosane Isabel Bittencourt; Jose Vassallo; Maria de Lourdes Lopes Ferrari Chauffaille; Sandra Guerra Xavier; Katia Borgia Pagnano; Ana Clara Kneese Nascimento; Carmino Antonio De Souza; Carlos Sergio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2012

7.  Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta-analysis.

Authors:  Erpeng Yang; Mingjing Wang; Ziqing Wang; Yujin Li; Xueying Wang; Jing Ming; Haiyan Xiao; Richeng Quan; Weiyi Liu; Xiaomei Hu
Journal:  Ann Hematol       Date:  2021-08-12       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.